Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
61°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vertex Pharmaceuticals Incorporated
< Previous
1
2
3
4
Next >
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
March 09, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7
February 21, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
February 07, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7
January 17, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9
January 04, 2023
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Investigational New Drug (IND) Application for VX-522, mRNA Therapy for People With Cystic Fibrosis, Cleared by FDA
December 12, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
December 10, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle (EEV) Therapeutics for Myotonic Dystrophy Type 1 (DM1)
December 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
TRDA
VRTX
Vertex to Participate in Upcoming Investor Conferences
November 09, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Partnership with Basketball Hall-of-Famer Alonzo Mourning to Raise Awareness of APOL1-Mediated Kidney Disease (AMKD)
November 04, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis Conference
November 03, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Third Quarter 2022 Financial Results
October 27, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Third Quarter 2022 Financial Results on October 27
October 13, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Advances Program Targeting Alpha-1 Antitrypsin Deficiency
October 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022
September 27, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Appoints Jonathan Biller as Chief Legal Officer
September 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
September 02, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in the Wells Fargo Healthcare Conference on Friday, September 9
August 31, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Advances VX-548 in Acute and Neuropathic Pain
July 22, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Announce Second Quarter 2022 Financial Results on August 4
July 18, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
July 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes
July 05, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress
June 11, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference
June 10, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15
June 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA
June 08, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
June 06, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress
June 02, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
CRSP
VRTX
Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference
May 31, 2022
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Tickers
VRTX
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.